Please login to the form below

Not currently logged in

Basilea appoints commercial head

David Veitch spent 15 years at BMS

Switzerland-based biopharma Basilea has appointed David Veitch as chief commercial officer, effective September 1, 2014.

Veitch will lead the company's commercial operations, including sales, marketing and pricing.

He joins from Savient Pharmacueticals where he served as president of the company's' European operations. It's at Bristol-Myers Squibb (BMS) where Veitch has spent most of his career, however, serving at the company from 1996 to 2011 when he joined Savient.

Veitch's most senior role at BMS was senior VP for EMEA marketing and brand commercialisation.

Ronald Scott, CEO of Basilea, commented that Veitch's “extensive experience and in-depth knowledge of European pharmaceutical markets will be instrumental” as the company prepares to launch its antibiotic Zevtera in Europe in 2015.

19th August 2014

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

When is it time to rebrand?
The Biosimilar Challenge
How health behaviours and clinical outcomes are related
When HCPs understand patient activation levels they can actively guide patients towards more confident self-management of diverse health concerns....